EUVIMEDEUVIMED entdecken
Crossref

Predicting the effect of hepatic disease on systemic drug exposure

Patrick J McNamara, Joseph Fleishaker, Darius Meiman

Journal of Pharmaceutical Sciences · 2026-06 · 115 (6) · 104136

DOI: 10.1016/j.xphs.2025.104136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2026-06. Verfasst von Patrick J McNamara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences College of Pharmacy University of Kentucky, 789 S. Limestone, 361 Lexington, KY 40536-0596, USA. Electronic add…. Hauptthemen laut MEDLINE: Liver Diseases. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to employ a comprehensive Top-Down scaling approach to estimate the impact of alterations in bioavailability (gut wall (FG) and hepatic first pass (FH,)) and clearance pathways (renal (ClR) and hepatic (ClH)) on the relative changes to drug exposure (AUCR, area under the curve ratio in liver disease compared to otherwise healthy patients). Observations evaluating drug clearance as a function of Child-Pugh (C-P) categories (mild, moderate, and severe) for hepatically cleared drugs (fe 2 in severe liver disease. The Top-Down scaling approach was comparable to bottom-up methods (PBPK) in predicting the relative changes to drug exposure (AUCR) for various degrees of liver disease based on C-P categories. Furthermore, this approach was able to highlight the key criteria for drugs with the highest risk of increased exposure (AUCR>2) in liver disease. These drugs are primarily eliminated via hepatic metabolism (fe < 0.5), and their clearance pathways include either one (or a combination) of CYP1A2, CYP2C19, CYP2D6, and CYP3A4. Oral administration significantly increases the risk of increased exposures, particularly those with substantial hepatic and gut wall first-pass (FH and FG) metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver DiseasesHumansArea Under CurvePharmaceutical PreparationsBiological AvailabilityMetabolic Clearance RateCytochrome P-450 Enzyme SystemLiverModels, Biological

Stichwörter der Autor:innen

CYP3A4Hepatic clearanceLiver diseaseRenal clearanceTop-down scaling

Substanzen

Pharmaceutical PreparationsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences College of Pharmacy University of Kentucky, 789 S. Limestone, 361 Lexington, KY 40536-0596, USA. Electronic address: pmcnamar@email.uky.edu.
  • FIG Consulting, LLC, 2633 Cayman Hts Lexington, KY 40509, USA.
  • Clinical Pharmacology, AbbVie Inc, 1 N. Waukegan Rd., Bldg. AP31-3 North Chicago, IL 60064, USA.

Zitieren

APA

McNamara, P. J., Fleishaker, J., & Meiman, D. (2026). Predicting the effect of hepatic disease on systemic drug exposure. Journal of Pharmaceutical Sciences, 115(6), 104136. https://doi.org/10.1016/j.xphs.2025.104136

Vancouver

McNamara PJ, Fleishaker J, Meiman D. Predicting the effect of hepatic disease on systemic drug exposure. Journal of Pharmaceutical Sciences. 2026;115(6):104136. doi:10.1016/j.xphs.2025.104136

BibTeX
@article{McNamara2026,
  author = {McNamara, Patrick J and Fleishaker, Joseph and Meiman, Darius},
  title = {Predicting the effect of hepatic disease on systemic drug exposure},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2026},
  volume = {115},
  number = {6},
  pages = {104136},
  doi = {10.1016/j.xphs.2025.104136}
}
Kostenlos starten →